OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study
In a multicentre phase 1 study, the recombinant overlapping peptide vaccine OVM-200 was found to be safe and well-tolerated while successfully breaking immune tolerance to the self-antigen survivin by inducing robust humoral and cellular immune responses in patients with advanced solid tumours, with higher immune responses correlating with stable disease.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human immune system is a formidable defense force, trained from birth to recognize and destroy invaders like bacteria and viruses. However, this same training creates a blind spot when it comes to cancer. Many cancers grow by hijacking normal proteins that the body already uses for essential tasks, such as cell division. Because these proteins are "self," the immune system is taught to ignore them, a state known as immune tolerance. This allows tumors to hide in plain sight, effectively camouflaged by the very biology of the host. Breaking this camouflage is one of the most difficult challenges in modern medicine. If scientists could teach the immune system to see these self-proteins as threats, it might be possible to train the body to attack the cancer cells that rely on them, without harming the healthy tissue that uses the same proteins for normal function.
A recent clinical trial has taken a significant step toward solving this problem by testing a new type of vaccine designed to break that specific blind spot. The study focused on a protein called survivin, which is found in high amounts in many types of advanced cancer but is rarely present in healthy adult tissues. While survivin is essential for cell division, its overexpression helps tumors survive treatment and grow unchecked. The challenge has been that because survivin is a natural part of the body, the immune system usually tolerates it. Researchers developed a vaccine called OVM-200, which is not a single piece of the protein but a re-engineered version made of many overlapping segments. This design allows the vaccine to present the full range of the protein to the immune system in a way that bypasses the usual tolerance mechanisms, essentially forcing the body to recognize the protein as foreign and dangerous.
The trial involved 27 patients with advanced forms of lung, ovarian, or prostate cancer who had already tried standard treatments without success. These patients received the vaccine under the skin every two weeks. The primary goal was to see if the treatment was safe and if it could actually trigger an immune response against survivin. The results showed that the vaccine was well tolerated. The side effects were mild, mostly limited to temporary redness or soreness at the injection site, and no serious or life-threatening reactions were linked to the vaccine itself. More importantly, the treatment successfully broke the immune system's silence. Before the vaccination, the patients had very low levels of antibodies and immune cells targeting survivin, despite their tumors being full of the protein. After receiving the vaccine, their bodies began producing a robust defense. The levels of antibodies specific to survivin rose dramatically, increasing from a baseline of 20 to a peak of over 80,000 in some measurements. Similarly, the number of immune cells capable of attacking survivin increased significantly, jumping from an average of about 17 cells to over 500 cells in the blood samples taken after vaccination.
The researchers also looked at how the number of doses affected the outcome. Patients who received four or more doses developed stronger immune responses than those who received fewer shots, suggesting that repeated exposure helps the body build a more powerful defense. When the team compared the immune responses to how the patients' diseases progressed, a clear pattern emerged. Patients whose cancer stopped growing or remained stable developed significantly higher levels of antibodies than those whose cancer continued to grow. One patient with advanced lung cancer, whose disease had progressed through multiple standard therapies, received eleven doses of the vaccine. This patient maintained stable disease for the duration of the study while developing extremely high levels of antibodies and immune cells, illustrating that the vaccine could sustain a strong immune attack in a real-world setting.
While the vaccine did not shrink the tumors in most patients during this early phase of testing, the findings provide strong evidence that the approach works. The study demonstrated that it is possible to overcome the body's natural tolerance to a cancer-associated protein and generate a potent immune response in patients with advanced disease. The fact that the immune response was linked to disease stability suggests that this strategy holds promise for controlling cancer growth. The researchers noted that the immune system's reaction to the vaccine was a clear signal that the body could be retrained to see the cancer's camouflage. This success lays the groundwork for future studies, potentially exploring whether combining this vaccine with other therapies or using it earlier in the disease course could lead to even better outcomes for patients. The work confirms that the immune system can be awakened to fight cancer, even when the target is a protein the body normally accepts.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.